Patents Assigned to HANGZHOU CALIBRA DIAGNOSTICS CO., LTD.
  • Patent number: 11923082
    Abstract: The present invention relates to a system for predicting gestational diabetes mellitus (GDM) of pregnant individuals, wherein the system comprises an operation module, and the operation model comprises a support vector regression model, and the system is used to predict the plasma glucose levels at 1 hour and/or 2 hours of oral glucose tolerance test (OGTT) by using a support vector regression developed prediction model generated by substituting the concentration of the biomarkers in fasting blood samples of pregnant individuals. The present invention provides biomarkers and biomarker-based diagnostic models for differential diagnosis of gestational diabetes mellitus (GDM), which can be applied to diagnosis or prediction of GDM in early stage and are of great significance to the prevention or treatment of GDM.
    Type: Grant
    Filed: June 10, 2022
    Date of Patent: March 5, 2024
    Assignees: HANGZHOU CALIBRA DIAGNOSTICS CO., LTD., HANGZHOU DIAN MEDICAL INSPECTION CENTER CO., LTD.
    Inventors: Huafen Liu, Ziqing Kong, Chao Zhang, Rongchang Chen, Yuning Zhu
  • Patent number: 11860171
    Abstract: In a screening kit and a confirmed and typing diagnosis system for primary aldosteronism, a sample is pretreated by a magnetic bead bonded with a balanced hydrophilic-lipophilic polymer on the surface thereof, and process conditions are optimized and the content of each the five markers such as, aldosterone in the sample is accurately detected by liquid chromatography-tandem mass spectrometry for one time, thus finding the optimal screening cut-off value of 20.4; when a positive result is judged, PA is confirmed and subjected to typing diagnosis according to the test values of the markers, thereby achieving the simultaneous detection of the content of each the five markers such as, aldosterone on the same platform. Therefore, the screening kit and confirmed and typing diagnosis system for primary aldosteronism are integrated with screening, confirmed and typing diagnosis functions, thus providing a reliable laboratory examination basis for clinicians to formulate an effective therapeutic regimen.
    Type: Grant
    Filed: April 21, 2023
    Date of Patent: January 2, 2024
    Assignee: HANGZHOU CALIBRA DIAGNOSTICS CO., LTD.
    Inventors: Pengyun Liu, Xiaofen Yuan, Jinfei Ma, Ziqing Kong, Yikun Li, Weijia Wu, Huafen Liu